Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H15N2O2.Cl |
Molecular Weight | 182.649 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)CCOC(N)=O
InChI
InChIKey=AIXAANGOTKPUOY-UHFFFAOYSA-N
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H15N2O2 |
Molecular Weight | 147.1955 |
Charge | 1 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
6.0 mM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | MIOSTAT Approved UseIntraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery. Launch Date8.6486401E10 |
PubMed
Title | Date | PubMed |
---|---|---|
Avoidance learning: long-lasting deficits after temporal lobe seizure. | 1969 Dec 12 |
|
[Tremor following intracerebral carbachol injection. 1.Carbachol sensitivity of various brain structures]. | 1975 |
|
Motor disturbances produced by intrastriatal injection of cyclic AMP and cyclic GMP. | 1976 Nov |
|
Muscarine- and carbachol-induced aggressions: fear and irritable kinds of aggressions. | 1977 Dec 28 |
|
[Effects of atropine and scopolamine on the aggressive behavior and convulsions induced by carbachol and eserine injected into the cerebral ventricles of the cat]. | 1980 |
|
Seizures induced by carbachol, morphine, and leucine-enkephalin: a comparison. | 1983 Apr |
|
Neuropharmacology of the parasitic trematode, Schistosoma mansoni. | 1983 Jan |
|
Drug-induced modulation of locomotor hyperactivity induced by picrotoxin in nucleus accumbens. | 1984 Oct |
|
Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". | 1984 Sep 3 |
|
Renal function during onset of carbachol-induced hypertension in conscious rats. | 1990 |
|
Catalepsy induced by carbachol microinjected into the pontine reticular formation of rats. | 1990 Jul 31 |
|
Interactions between limbic, thalamo-striatal-cortical, and central autonomic pathways during epileptic seizure progression. | 1999 Aug 16 |
|
Myoclonic and tonic seizures elicited by microinjection of cholinergic drugs into the inferior colliculus. | 1999 Sep-Oct |
|
Chick optic lobe contains a developmentally regulated alpha2alpha5beta2 nicotinic receptor subtype. | 2000 Aug |
|
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines. | 2002 Aug |
|
Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate. | 2002 Feb |
|
Impaired parasympathetic heart rate control in mice with a reduction of functional G protein betagamma-subunits. | 2002 Feb |
|
Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart. | 2002 May |
|
Zebrafish M2 muscarinic acetylcholine receptor: cloning, pharmacological characterization, expression patterns and roles in embryonic bradycardia. | 2002 Nov |
|
Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. | 2003 Aug 22 |
|
Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. | 2003 Dec |
|
Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze. | 2003 Mar |
|
Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics. | 2003 Oct |
|
Crucial role of histamine for regulation of gastric acid secretion ascertained by histidine decarboxylase-knockout mice. | 2003 Oct |
|
TNF-alpha hyperpolarizes membrane potential and potentiates the response to nicotinic receptor stimulation in cultured rat myenteric neurones. | 2004 May |
|
Case report: acute unintentional carbachol intoxication. | 2006 |
|
Muscarinic acetylcholine receptors mediate oligodendrocyte progenitor survival through Src-like tyrosine kinases and PI3K/Akt pathways. | 2006 Apr |
|
Roles of protein kinase C, Ca2+, Pyk2, and c-Src in agonist activation of rat lacrimal gland p42/p44 MAPK. | 2006 Aug |
|
Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block. | 2007 May |
|
A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. | 2008 Apr |
|
Enhanced proliferation of SNU-407 human colon cancer cells by muscarinic acetylcholine receptors. | 2008 Nov 30 |
|
The cholinomimetic agent carbachol induces headache in healthy subjects. | 2009 Feb |
|
Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. | 2010 Mar |
|
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. | 2011 Feb 18 |
|
Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). | 2011 Sep 25 |
|
Characterisation of acetylcholinesterase release from neuronal cells. | 2013 Mar 25 |
Patents
Sample Use Guides
MIOSTAT (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27118568
In the dose-course studies, carbachol showed significant increase in phosphorylation of MYPT1 at Thr696 (p-MYPT1) from concentrations of 15-100 μM based on Western blot results (p < 0.05, ANOVA test). In the time-course studies, treatment of cells with 15 μM of carbachol significantly enhanced the expression of p-MYPT1 from 3 to 15 h (p < 0.05, ANOVA test) and induced the expression of Rho A from 10 to 120 min (p < 0.05, ANOVA test).
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:42:36 UTC 2023
by
admin
on
Wed Jul 05 22:42:36 UTC 2023
|
Record UNII |
8Y164V895Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
||
|
WHO-ATC |
S01EB02
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
||
|
WHO-ATC |
N07AB01
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
||
|
NDF-RT |
N0000175884
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
||
|
WHO-VATC |
QS01EB02
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
||
|
WHO-VATC |
QA03AB92
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5831
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
C47430
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
DB00411
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
32865
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
488
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
SUB06087MIG
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
298
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
M3051
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | Merck Index | ||
|
D002217
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
CHEMBL965
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
DTXSID9022730
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
3385
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
51-83-2
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
6373
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
1092009
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
1999
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | RxNorm | ||
|
383
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
Carbachol
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
100000081628
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
200-127-3
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY | |||
|
Carbachol
Created by
admin on Wed Jul 05 22:42:36 UTC 2023 , Edited by admin on Wed Jul 05 22:42:36 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Duration of Action | PHARMACOKINETIC |
|
INTRAOCULAR ADMINISTRATION PHARMACOKINETIC |
|
||